Cardinal Health set a fresh 52-week high following a string of bullish analyst actions. Wells Fargo raised its price target to $237 and maintained an overweight rating, marking the third upward revision from the firm in six months. UBS lifted its objective to $220 and reiterated a buy call, while Citigroup moved to a buy rating with a target of $244. In total, 14 analysts hold a buy recommendation, two rate the stock as hold, and the consensus price target stands at $216.33.

Institutional investors continue to consolidate positions in Cardinal Health. SJS Investment Consulting increased its stake by 1,363.6% during the third quarter, adding 150 shares. Barnes Dennig Private Wealth boosted holdings by 38.7% in the fourth quarter, and Atlantic Edge Private Wealth Management enlarged its position by 75% earlier in the year. Overall, 87.17% of outstanding shares are held by institutions, reflecting strong confidence at the professional level.

In the latest quarter, Cardinal Health reported revenue growth of 22.4% year-over-year, generating $64.01 billion in sales and delivering $2.55 in EPS, topping consensus by $0.33. The company erased a net margin of 0.68% and posted a negative return on equity of 84.37%. Management issued guidance of $9.65 to $9.85 EPS for fiscal 2026, while analysts foresee a full-year EPS of $7.95. The board declared a quarterly dividend of $0.5107 per share, translating to a 1.0% yield and a 30.77% payout ratio.